First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus
Authors:
- Anita KapurAKAnita Kapur
- Robin O’connor-SemmesRORobin O’connor-Semmes
- Elizabeth K HusseyEHElizabeth K Hussey
- Robert L DobbinsRDRobert L Dobbins
- Wenli TaoWTWenli Tao
- Marcus HompeschMHMarcus Hompesch
- Glenn A SmithGSGlenn A Smith
- Joseph W PolliJPJoseph W Polli
- Charles D James JrCJCharles D James Jr
- Imao MikoshibaIMImao Mikoshiba
- Derek J NunezDNDerek J Nunez
Open Access
- 13 May 2013
- journal article
- research article
- Published by Springer Nature in BMC Pharmacology and Toxicology
- Vol. 14 (1) , 26
Abstract
Remogliflozin etabonate (RE) is the prodrug of remogliflozin, a selective inhibitor of the renal sodium-dependent glucose transporter 2 (SGLT2), which could increase urine glucose excretion (UGE) and lower plasma glucose in humans. This double-blind, randomized, placebo-controlled, single-dose, dose-escalation, crossover study is the first human trial designed to evaluate safety, tolerability, pharmacokinetics (PK) and pharmacodynamics of RE. All subjects received single oral doses of either RE or placebo separated by approximately 2 week intervals. In Part A, 10 healthy subjects participated in 5 dosing periods where they received RE (20 mg, 50 mg, 150 mg, 500 mg, or 1000 mg) or placebo (4:1 active to placebo ratio per treatment period). In Part B, 6 subjects with type 2 diabetes mellitus (T2DM) participated in 3 dose periods where they received RE (50 mg and 500 mg) or placebo (2:1 active to placebo per treatment period). The study protocol was registered with the NIH clinical trials data base with identifier NCT01571661 . RE was generally well-tolerated; there were no serious adverse events. In both populations, RE was rapidly absorbed and converted to remogliflozin (time to maximum plasma concentration [Cmax;Tmax] approximately 1 h). Generally, exposure to remogliflozin was proportional to the administered dose. RE was rapidly eliminated (mean T½ of ~25 min; mean plasma T½ for remogliflozin was 120 min) and was independent of dose. All subjects showed dose-dependent increases in 24-hour UGE, which plateaued at approximately 200 to 250 mmol glucose with RE doses ≥150 mg. In T2DM subjects, increased plasma glucose following OGTT was attenuated by RE in a drug-dependent fashion, but there were no clear trends in plasma insulin. There were no apparent effects of treatment on plasma or urine electrolytes. The results support progression of RE as a potential treatment for T2DM. ClinicalTrials.gov NCT01571661Keywords
This publication has 27 references indexed in Scilit:
- Human Hepatic Cytochrome P450-Specific Metabolism of the Organophosphorus Pesticides Methyl Parathion and DiazinonDrug Metabolism and Disposition, 2012
- Immunoassays for the incretin hormones GIP and GLP-1Best Practice & Research Clinical Endocrinology & Metabolism, 2009
- Is the current therapeutic armamentarium in diabetes enough to control the epidemic and its consequences? What are the current shortcomings?Acta Diabetologica, 2009
- Renal sodium–glucose transport: role in diabetes mellitus and potential clinical implicationsKidney International, 2009
- Sodium–glucose co‐transporter‐2 inhibitors: an emerging new class of oral antidiabetic drugDiabetes, Obesity and Metabolism, 2008
- 10-Year Follow-up of Intensive Glucose Control in Type 2 DiabetesNew England Journal of Medicine, 2008
- Remogliflozin Etabonate, in a Novel Category of Selective Low-Affinity Sodium Glucose Cotransporter (SGLT2) Inhibitors, Exhibits Antidiabetic Efficacy in Rodent ModelsThe Journal of Pharmacology and Experimental Therapeutics, 2008
- Phlorizin: a reviewDiabetes/Metabolism Research and Reviews, 2004
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)The Lancet, 1998
- Molecular Characteristics of Na+-coupled Glucose Transporters in Adult and Embryonic Rat KidneyJournal of Biological Chemistry, 1995